Hemodynamic effects of lisinopril, a new angiotensin converting enzyme inhibitor. and betaxolol, a new .BETA.1-selective .BETA.-blocking agent, in essential hypertension.
スポンサーリンク
概要
- 論文の詳細を見る
Hemodynamic effects of lisinopril, a new angiotensin converting enzyme inhibitor, and betaxolol, a new β<SUB>1</SUB>-selective β-blocking agent, were evaluated in 21 outpatients with essential hypertension (WHO I / II stage) introducing them orally for six wks. Lisinopril (mean dose, 13.5 ±2.2 (SEM) mg/day) and betaxolol (8.4 ± 1.9 mg/day) reduced blood pressure (lisinopril, 176/103 ± 7/2 to 154/88±6/3 mmHg, P<0. 01; betaxolol, 171/107 ± 5/2 to 152/92±5/2 5/2 mmHg, P< 0.005) with different effects on heart rate ; betaxolol reduced heart rate significantly (66 ± 2 to 61 ± 3 bpm, P< 0.01) but lisinopril did not (71 ± 3 to 71 ± 3 bpm). These two drugs did not induce any significant change in circulating blood volume (measured using <SUP>131</SUP>I-labeled human serum albumin) (lisinopril, 2. 95 ± 0. 17 to 2. 93 ± 0.15 <I>l</I>/m<SUP>2</SUP> ; betaxolol, 2.80± 0.08 to 2.77± 0.09 l/m2) and cardiac output (measured using <SUP>99m</SUP>Tc in vivo labeled red cells) (lisinopril, 3.19 ± 0.20 to 3. 19 ±0.19 l/min/m2 ; betaxolol, 3.23 ± 0.09 to 3.19 ±0.16 <I>l</I>/min/m2). Both of them induced a slight and insignificant increase in left ventricular ejection fraction (LVEF) and reduced total peripheral resistance index (lisinopril, 3, 302 ± 196 to 2, 828 ± 150 dyn·sec·cm<SUP>-5</SUP>·m<SUP>2</SUP>, P<0.01; betaxolol, 3, 179 ± 75 to 2, 856 ± 167 dyn·sec·cm<SUP>-5</SUP>·m<SUP>2</SUP>), though the decrease in the betaxolol group was not significant.<BR>These effects in the lisinopril-treated group may be attributable to angiotensin converting enzyme inhibiting activity mainly in vascular beds. As β<SUB>1</SUB>-selective β-blocking agents without vasodilating properties, such as atenolol and metoprolol, were reported to reduce cardiac pump function without decrease in peripheral resistance, and celiprolol, one with vasodilating properties, was reported to reduce peripheral resistance in essential hypertension, these results obtained in the betaxolol-treated group warrant a further investigation on its vasodilating properties.
- 一般社団法人 日本臨床薬理学会の論文
著者
関連論文
- 特発性肺動脈拡張症の1例 : 日本循環器学会第104回関東甲信越地方会
- 降圧薬治療(ACE阻害薬を含む)と癌
- II.診断と治療の進め方 7.降圧薬の開始時期と降圧目標
- 新しいβ遮断薬TN-891とDihydropyridine系Ca拮抗薬GJ-0956の本態性高血圧例における循環動態上の効果
- 本態性高血圧例における新しいCa拮抗薬 Monatepil (AJ-2615) の循環動態上の効果
- 本態性高血圧・高脂血症合併例における高脂血症治療薬 Pravastatin と Bezafibrate の効果
- 本態性高血圧例におけるCa拮抗薬SD-3211(Semotiadil Fumarate)の循環動態上の効果
- 1238 本態性高血圧における血管拡張性降圧薬(AII受容体拮抗薬、K channel開口薬、Ca拮抗薬)の循環動態上の効果
- 本態性高血圧における循環動態の縦断的な検討 : 口述発表 : 第57回日本循環器学会学術集会
- 悪性腫瘍の心転移についての臨床病理学的検討(日本循環器学会 第138回関東甲信越地方会)
- 48) Osler-Rendu-Weber症候群の1例 : 日本循環器学会第122回関東甲信越地方会
- 本態性高血圧のcentral hemodynamicsとβ遮断薬metoprololの効果
- 22)Sjogren症候群に合併したrenal tubular acidosisの1例 : 日本循環器学会第107回関東甲信越地方会
- 74) 急性冠症候群を発症した先天性C3欠損症と高Lp(a)血症を伴う若年SLE女性の1例
- 8) 房室一時ペーシングによるAV delay設定によって左室流出路圧較差の改善を認めた閉塞性肥大型心筋症の1例
- 86)塩酸アブリンジンによる急性間質性肺炎の一例
- 患者サイドに立った最近の降圧薬の使い方-2-
- 患者サイドに立った最近の降圧薬の使い方-1-(これからの医療-62-)
- Penbutolol
- 本態性高血圧の一次予防(高血圧発症の予測因子と一次予防効果) : 欧米諸国の研究成績を中心とした検討
- 4. 降圧薬の将来展望 : 3)交感神経抑制薬
- 放射線照射17年後に発症した収縮性心膜炎の1例
- Effect of nipradilol on LV heart muscle weight and extension facility in essential hypertension.
- Choice of antihypertensive agents in hemodynamic aspects to match pathophysiology and pharmacology in essential hypertension.
- :Cardiac Output/Cardiopulmonary Blood Volume in Essential Hypertension
- Haemodynamic Effects of Once Daily Atenolol in Essential Hypertension
- Hemodynamic effects of tilisolol, a new .BETA.-adrenergic blocking agent with vasodilating property, and doxazosin, a new .ALPHA.-adrenergic blocking agent, in essential hypertension.
- Effect of combined use of vasodilative antihipertensive agent, pinacidil and ACE inhibitor, alacepril on circulatory dinamics in patient with essential hypertension receiving .BETA. blocker.
- Effect of a HMG-CoA reductase inhibitor, pravastatin on essential hypertension combining hyperlipidemia.
- Hemodynamic effects of lisinopril, a new angiotensin converting enzyme inhibitor. and betaxolol, a new .BETA.1-selective .BETA.-blocking agent, in essential hypertension.
- タイトル無し
- タイトル無し
- タイトル無し